

ABSTRACT

The present invention relates to compositions of the polypeptide [[EEIIMD, anti-LRP antibodies, LRP antagonists,]] EEIIMD [[and/or]] and one or more fibrinolytic agents [[comprising]] selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, [[and/or]] or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

(78 words)